It is likely that patients with ALK+ or EGFR mutation+ lung cancer or breast cancer brain metastases that are hormone or HER2 responsive and who are deemed highly likely to have a response to systemic therapy could have radiosurgical treatment deferred without an impact on quality of life or survival probabilities. This evidence concerns the gene EGFR and breast cancer.